Biology Reference
In-Depth Information
10. Howard KA (2009) Delivery of RNA interference therapeutics using polycation-based
nanoparticles. Adv Drug Deliv Rev 61(9):710-720
11. de Fougerolles A, Novobrantseva T (2008) siRNA and the lung: research tool or therapeutic
drug? Curr Opin Pharmacol 8(3):280-285
12. Merkel OM, Kissel T (2012) Nonviral pulmonary delivery of siRNA. Acc Chem Res
45(7):961-70. doi:10.1021/ar200110p
13. Nielsen EJB, Nielsen JM, Becker D et al (2010) Pulmonary gene silencing in transgenic
EGFP mice using aerosolised chitosan/siRNA nanoparticles. Pharm Res 27(12):2520-2527
14. DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, Meyers
R, Gollob J, Vaishnaw A (2010) A randomized, double-blind, placebo-controlled study of an
RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA
107(19):8800-8805
15. McAuley JL, Linden SK, Png CW, King RM, Pennington HL, Gendler SJ, Florin TH, Hill
GR, Korolik V, McGuckin MA (2007) MUC1 cell surface mucin is a critical element of the
mucosal barrier to infection. J Clin Invest 117(8):2313-2324
16. Strombeck DR, Harrold D (1974) Binding of cholera toxin to mucins and inhibition by gas-
tric mucin. Infect Immun 10(6):1266-1272
17. Cone RA (2009) Barrier properties of mucus. Adv Drug Deliv Rev 61(2):75-85
18. Lai SK, Wang Y-Y, Wirtz D, Hanes J (2009) Micro- and macrorheology of mucus. Adv Drug
Deliv Rev 61(2):86-100
19. Copeman M, Matuz J, Leonard AJ, Pearson JP, Dettmar PW, Allen A (1994) The gastroduo-
denal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16
dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate. J
Gastroenterol Hepatol 9(Suppl 1):S55-S59
20. Pullan RD, Thomas GA, Rhodes M, Newcombe RG, Williams GT, Allen A, Rhodes J (1994)
Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis.
Gut 35(3):353-359
21. Greaves JL, Wilson CG (1993) Treatment of diseases of the eye with mucoadhesive delivery
systems. Adv Drug Deliv Rev 11(3):349-383
22. Prydal JI, Artal P, Woon H, Campbell FW (1992) Study of human precorneal tear fi lm thick-
ness and structure using laser interferometry. Invest Ophthalmol Vis Sci 33(6):2006-2011
23. Clunes MT, Boucher RC (2007) Cystic fibrosis: the mechanisms of pathogenesis of an inher-
ited lung disorder. Drug Discov Today Dis Mech 4(2):63-72
24. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC (1998)
Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the patho-
genesis of cystic fibrosis airways disease. Cell 95(7):1005-1015
25. Tarran R, Grubb BR, Gatzy JT, Davis CW, Boucher RC (2001) The relative roles of passive
surface forces and active ion transport in the modulation of airway surface liquid volume and
composition. J Gen Physiol 118(2):223-236
26. Verkman AS, Song Y, Thiagarajah JR (2003) Role of airway surface liquid and submucosal
glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol 284(1):C2-C15
27. Rosen H, Abribat T (2005) The rise and rise of drug delivery. Nat Rev Drug Discov
4(5):381-385
28. Mrsny RJ (2009) Lessons from nature: “Pathogen-Mimetic” systems for mucosal nano-
medicines. Adv Drug Deliv Rev 61(2):172-192
29. Cohn L (2006) Mucus in chronic airway diseases: sorting out the sticky details. J Clin Invest
116(2):306-308
30. Hogg JC, Chu F, Utokaparch S et al (2004) The nature of small-airway obstruction in chronic
obstructive pulmonary disease. N Engl J Med 350(26):2645-2653
31. Merkus V, Schipper M (1998) Nasal mucociliary clearance as a factor in nasal drug delivery.
Adv Drug Deliv Rev 29(1-2):13-38
32. Ali MS, Pearson JP (2007) Upper airway mucin gene expression: a review. Laryngoscope
117(5):932-938
33. Lehr C-M, Poelma FGJ, Junginger HE, Tukker JJ (1991) An estimate of turnover time of
intestinal mucus gel layer in the rat in situ loop. Int J Pharm 70(3):235-240
Search WWH ::
Custom Search